Current and Prospective Therapies for Double-Hit Lymphoma
In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma.
Latest Features
LATEST ARTICLES
Alcohol and Prostate Cancer: How Is Intake Associated With Risk of Death and/or Metastasis?
This data analysis examined the effect of alcohol consumption on the risk of lethal prostate cancer in men at risk of the disease, and those who developed nonmetastatic prostate cancer during follow-up.
Analysis Sheds Light on Bevacizumab “Reversals” in Glioblastoma
Improvements to PFS and “clinically meaningful reductions in daily corticosteroid use” were said to be linked to the addition of bevacizumab in glioblastoma.
The Evolution of Frontline Hodgkin Lymphoma Treatment
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Emerging Pomalidomide-Based Triplet Therapies for Multiple Myeloma
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
Multidisciplinary Genetic Tumor Boards: Critical for Interpreting Tumor-Only Sequencing Results
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results.
The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma
Updated guidelines advised against performing cytoreductive nephrectomy in poor-risk patients.
Tumors With High Levels of Microsatellite Instability Responded Well to Treatment With PD-1 Inhibitors
New research has linked microsatellite instability and the number of insertion/deletion mutations present in a tumor to clinical response to checkpoint inhibition.
Evaluating the Cost-Effectiveness of Acute Myeloid Leukemia Treatment
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
Research Shows How Talc Powder May Change Ovarian Cancer Cells
Prospective studies on talc and cancer are necessary to fully form our collective understanding of talc’s risks.
The Revival of a Forgotten Cancer Gene Therapy With Off-the-Shelf Potential
A universal cancer gene therapy from the early 2000s is headed into phase 2 trials, in light of renewed interest and outlier patients who are still alive at 10 years later.
Looking Back to Go Forward: CAR-T Cell Therapy in R/R CLL
Research suggests that ibrutinib may have the ability to alter the phenotype of a final CAR-T cell product.
IL-2 and Metastatic Renal Cell Carcinoma
Despite a challenging toxicity profile, high dose interleukin-2 (HD IL-2), one of the earliest-approved immunotherapies for metastatic renal cell carcinoma still has a role in treating selected patients, a new registry analysis shows.
Screening Beyond 5 Years Reduces Risk of Lung Cancer-Specific Mortality by 39%
An Italian trial reported fewer deaths with annual or biennial low-dose CT lung screening—and an active surveillance approach reduced overdiagnosis.
Pembrolizumab Shows Promise in Post-ASCT Hodgkin Lymphoma
Pembrolizumab improved PFS in this high-risk patient population, but a randomized controlled trial is warranted.
Want to read more?
Please login or register first to view this content.
